Malta - angličtina - Medicines Authority

associated drug co. limited triq l-esportaturi, zone 1 central business district birkirkara cbd 1040 , malta - terbutaline sulfate - inhalation powder - terbutaline sulfate 500 µg/spray - drugs for obstructive airway diseases

Spojené státy - angličtina - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the effect of intravenous magnesium on milk production is unknown. the developmental and health benefits to the neonate of breastfeeding should be considered along with the mother's clinical need for magnesium sulfate in 5% dextrose injection and any potential adverse effects on the breastfed infant from magnesium sulfate in 5% dextrose injection or from the underlying maternal condition. the safety and effectiveness of magnesium sulfate in 5% dextrose injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see dosage and administration (2.2)] . magnesium is excreted solely by the kidneys. patients with severe renal impairment (urine output less than 100 ml per 4 hours) are at greater risk for increased magnesium concentrations that may lead to magnesium toxicity [see warnings and precautions (5.2) and clinical pharmacology (12.3)] . in patients with severe renal impairment, dosage reduction is recommended and the maximum recommended dosage is lower than patients with normal renal function [see dosage and administration (2.3)] .

Spojené státy - angličtina - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 10 mg in 1 ml - magnesium sulfate in 5% dextrose injection is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

b & s healthcare - terbutaline sulfate - powder for inhalation - 500 microgram

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

imbat limited - terbutaline sulfate - powder for inhalation - 500 mcg/acutuation - selective beta-2-adrenoreceptor agonists; terbutaline

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.3 mg/ml - elixir - 1.5 mg/5ml - active: terbutaline sulfate 0.3 mg/ml excipient: citric acid citric acid monohydrate disodium edetate dihydrate ethanol lemon-limette glycerol purified water raspberry sodium benzoate sodium hydroxide sorbitol

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.5 mg/ml - solution for injection - 0.5 mg/ml - active: terbutaline sulfate 0.5 mg/ml excipient: sodium chloride water for injection

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 2.5mg - tablet - 2.5 mg - active: terbutaline sulfate 2.5mg excipient: ethanol lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone purified water

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 5mg - tablet - 5 mg - active: terbutaline sulfate 5mg excipient: ethanol lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone purified water

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.25mg - aerosol inhaler, metered dose - 0.25 mg/dose - active: terbutaline sulfate 0.25mg excipient: cryofluorane dichlorodifluoromethane sorbitan trioleate trichlorofluoromethane